摘要
目的探讨脾氨肽口服溶液预防性治疗季节性过敏性鼻炎(AR)的临床效果和对免疫功能的影响。方法选取2015年5月至2019年5月在内蒙古医科大学附属医院就诊的52例季节性AR患者作为研究对象,采用随机数字表法分为A组(20例)、B组(20例)和C组(12例)。A组采用单独脾氨肽口服溶液治疗,B组采用脾氨肽口服溶液和氯雷他定联合用药治疗,C组单独采用氯雷他定治疗。三组均在发病期前进行预防性干预治疗,比较三组患者采用不同药物治疗对季节性AR患者症状、生活质量、合并用药以及辅助性T细胞(Th)亚群(Th1/Th2)型细胞因子等的影响。结果用药2周,B组的简要鼻结膜炎生活质量问卷(RQLQ)总分及各分项评分均低于C组,差异有统计学意义(P<0.05)。用药4周,B组的症状评分总分低于C组,差异有统计学意义(P<0.05);B组的RQLQ总分及各分项评分均低于C组,差异有统计学意义(P<0.05)。用药12周,B组的鼻部症状、情感改善评分低于C组,A组的鼻部症状评分低于C组,差异有统计学意义(P<0.05)。花粉高峰期(用药4、8周),B组的合并用药评分低于A组和C组,差异有统计学意义(P<0.05)。用药前后Th1/Th2的细胞因子检测显示,A组用药后的白细胞介素(IL)-2、γ干扰素(IFN-γ)、IL-4、IL-10水平高于用药前,差异有统计学意义(P<0.05);B组用药后的IL-2、IFN-γ、肿瘤坏死因子-α(TNF-α)、IL-4、IL-6、IL-10水平均高于用药前,差异有统计学意义(P<0.05);C组用药后的IL-2、IFN-γ、IL-4、IL-10水平均高于用药前,差异有统计学意义(P<0.05)。三组用药后的细胞因子水平比较,差异无统计学意义(P>0.05)。结论联用脾氨肽口服溶液和氯雷他定预防性治疗过敏性鼻炎可有效改善患者症状,提升患者生活质量,影响Th1/Th2类细胞因子水平,疗效显著。
Objective To investigate the clinical effect of Spleen Aminopeptide Oral Solution(SAOS)in the prophylactic treatment of seasonal allergic rhinitis(AR)and its effect on immune function.Methods A total of 52 patients with seasonal AR who were treated in the Affiliated Hospital of Inner Mongolia Medical University from May 2015 to May 2019 were selected as the research objects,and they were divided into group A(n=20),group B(n=20)and group C(n=12)according to the random number table method.Patients in group A received SAOS alone,group B received both SAOS and Loratadine,group C received Loratadine alone.The three groups were given different preventive intervention before the onset of AR.The influence of different drugs on the symptoms,quality of life,combined medication and T helper lymphocyte(Th)subsets(Th1/Th2)cytokines of patients with seasonal AR were compared among the three groups.Results At 2 weeks of treatment,the total score and sub item score of rhino-conjunctivitis quality of life questionnaire(RQLQ)in group B were lower than those in group C,the differences were statistically significant(P<0.05).At 4 weeks of treatment,the total symptom score of group B was lower than that of group C,the difference was statistically significant(P<0.05).The total score and sub item score of RQLQ in group B were lower than those of group C,the differences were statistically significant(P<0.05).At 12 weeks of treatment,the scores of nasal symptoms and emotional reactions of group B were lower than those of group C,and the nasal symptoms score of group A was lower than those of group C,the differences were statistically significant(P<0.05).In the pollen peak period(4 and 8 weeks of medication),the score of combined medication of group B was lower than that of group A and group C,the differences were statistically significant(P<0.05).Cytokine detection of Th1/Th2 showed that the levels of interleukin(IL)-2,interferon-γ(IFN-γ),IL-4,IL-10 in group A after treatment were higher than those before treatment,and the differences w
作者
崔彦儒
崔晓波
侯红枝
CUI Yanru;CUI Xiaobo;HOU Hongzhi(Department of Otolaryngology,Affiliated Hospital of Inner Mongolia Medical University,Inner Mongolia Autonomous Region,Hohhot 010050,China)
出处
《中国当代医药》
CAS
2022年第18期97-102,共6页
China Modern Medicine
关键词
过敏性鼻炎
季节性
免疫调节剂
脾氨肽
预防性治疗
Allergic rhinitis
Seasonal
Immunomodulators
Spleen Aminopeptide
Prophylactic treatment
